Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

AnaptysBio, Celgene sign strategic antibody discovery partnership

PBR Staff Writer Published 10 April 2012

AnaptysBio has entered into a strategic partnership with Celgene to develop antibodies against multiple therapeutic targets.

As per the agreement, AnaptysBio will use its SHM-XEL platform to produce therapeutic antibodies to oncology and inflammation-related targets.

Celgene will gain worldwide rights to develop and commercialize antibodies discovered by AnaptysBio.

AnaptysBio is eligible to receive an upfront payment, preclinical and clinical milestone payments from Celgene, as well as royalties upon sales of each product resulting from the partnership.

AnaptysBio president and chief executive officer Hamza Suria said: "We look forward to advancing novel antibody therapeutics with Celgene, in parallel with our internal pipeline programs."

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.